ClinicalTrials.gg
CompletedNCT00354965Updated Aug 1, 2017

Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adolescent Patients

A Phase 1 interventional study of amoxicillin/clavulanate potassium in Infections, Respiratory Tract, sponsored by GlaxoSmithKline. Completed at 6 sites in United States. Open to participants aged Up to 16 Years. Per ClinicalTrials.gov, last updated 2017-08-01.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2006, registered Jul 2006).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
Up to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Respiratory Tract Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Respiratory Tract Infections · GlaxoSmithKline.

Enrollment
7th of 19
52 · median 46
Started
2006
with 1 other
Phase 1
14 of 21
none open now
Registered
1st of 21
by date

Among the 21 studies in Respiratory Tract Infections by GlaxoSmithKline, this one is the 7th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2006, is one of 14 in phase 1, and was the 1st registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

None of the 21 studies in Respiratory Tract Infections by GlaxoSmithKline is open now. The open studies under Respiratory Tract Infections, anywhere →

Who these studies take

Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.

This study: Up to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Respiratory Tract Infections by GlaxoSmithKline as a file.
02

Study summary

Clinical research study to test amoxicillin and clavulanate tablet formulation for use in Acute Bacterial Sinusitis (ABS) in adolescent patients weighing at least 40 kilogram (kg) and no more than 16 years old. ABS is an acute bacterial infection of the sinus. The purpose of this study is to find out how children tolerate Augmentin XR and what happens to Augmentin XR in the body after it has been swallowed by children.

03

Conditions studied

  • Infections, Respiratory Tract

Keywords

  • ABS
  • Acute Bacterial
  • Sinusitis
  • Bacterial Sinusitis
04

Who can participate

Ages eligible
Up to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient weighs at least 40 kg.
  • Younger than 16 years old (no older than their 16th birthday).
  • Suspected acute bacterial sinusitis.
  • Able to swallow amoxicillin/clavulanate tablets.

Exclusion criteria

Exclusion criteria:

  • Personal or family history of adverse reactions or or allergy to any penicillin or cephalosporin antibiotics.
  • History of reaction to multiple allergens (if considered by the principal investigator).
  • Patient is participating in another clinical trial or has received or anticipates receiving an drug, vaccine, or medical device prior to the first dose of study medication or during the conduct of the study.
  • History or presence of gastrointestinal, hepatic or renal disease or other conditions known to or that may interfere with the absorption, distribution, metabolism or excretion of study medication.
  • Treatment with probenecid or allopurinol within 7 days of study entry.
  • Female patients with a positive urine hCG (human chorionic gonadotropin) test at screening, or who are lactating (breast feeding) or are unwilling to be abstinent until completion of the follow-up visit.
  • History of diarrhea due to Clostridium difficile following treatment with antibiotics.
  • History of hypersensitivity or allergy to heparin or related preparations (if the clinical research unit uses heparin to maintain intravenous cannula patency).
  • Patient is diagnosed with mononucleosis.
  • Estimated (GFR) \<40 ml/min.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    ARM 1

    Drug: amoxicillin/clavulanate potassium

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic data on amoxicillin/clavulanate

    Time frame: Time above MIC (T>MIC)for amoxicillin when amoxicillin/clavulanate is given orally twice daily to adolescents.

Secondary outcomes

  1. Safety, tolerability, and clinical response of oral amoxicillin/clavulanate

    Time frame: twice daily for 10 days in adolescent patients.

07

Study locations

6 sites
  • GSK Investigational Site
    Little Rock, Arkansas 72202, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    North Dartmouth, Massachusetts 02747, United States
  • GSK Investigational Site
    Sylva, North Carolina 28779, United States
  • GSK Investigational Site
    Cleveland, Ohio 44106, United States
  • GSK Investigational Site
    Erie, Pennsylvania 16506, United States
08

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2006 to primary completion in Apr 2007, 14 months.

Of 26 industry-sponsored phase 1 interventional studies under Respiratory Tract Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 14 months is above that.

Counting every sponsor, half of 35 studies reached it within 8 months; a quarter within 1 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2006
First posted
Jul 20, 2006
StartActual
Jan 19, 2006
Primary completionActual
Apr 2, 2007
CompletionActual
Apr 2, 2007
Last update
Aug 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00354965
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 20, 2006
Start date
Jan 19, 2006
Primary completion
Apr 2, 2007
Completion
Apr 2, 2007
Last update
Aug 1, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amoxicillin · Clavulanic Acid

Start the discussion